Figure S14 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity

Fig. S14. Effect of HDAC6 inhibitors at the indicated concentrations and times on a. proteasome activity and b. cell viability. Panel c. shows the effect of non-specific HDAC inhibitors on proteasome activity and cell viability. In panels a, b, and c, MM cells (50,000/well) were incubated with each pharmacologic at 1 uM for 72 h. Cell viability was determined using the XTT assay. d. Effect of HAT activators on proteasome activity and cell viability. MM cells (50,000/well) were incubated with each pharmacologic at 1 uM for 72 h. Cell viability was determined using the XTT assay.